Source-grounded facts extracted from Gossamer Bio, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Gossamer Bio, Inc. incurred convertible notes of $65,174,000 in aggregate principal amount of New Convertible Notes with U.S. Bank Trust Company, National Association at 7.50% per annum maturing July 1, 2030.
“the Company issued (i) $65,174,000 in aggregate principal amount of New Convertible Notes”
Gossamer Bio, Inc. entered into Purchase Warrant Agreement with Computershare, Inc., as warrant agent (effective 2026-06-04).
“a warrant agreement, dated as of June 4, 2026 (the “Purchase Warrant Agreement”), by and between the Company and Computershare, Inc., as warrant agent (the “Warrant Agent”).”
Gossamer Bio, Inc. entered into New Convertible Notes Indenture with U.S. Bank Trust Company, National Association, as trustee and collateral agent (effective 2026-06-04).
“an indenture, dated as of June 4, 2026 (the “New Convertible Notes Indenture”), by and between the Company, the guarantors party thereto and U.S. Bank Trust Company, National Association, as trustee and collateral agent (in such capacity, the “Collateral Agent”).”
Gossamer Bio, Inc. shareholders approved Advisory approval of the compensation of the Company's named executive officers.
“The compensation of the named executive officers was approved, on an advisory basis, by the votes indicated: For Against Abstain Broker Non-Votes 111,286,550 7,545,502 137,461 45,450,098”
Gossamer Bio, Inc. shareholders approved Ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
“The selection was ratified by the votes indicated: For Against Abstain Broker Non-Votes 163,185,993 1,192,448 41,170 —”
Gossamer Bio, Inc. shareholders approved Election of two Class II directors for a three-year term to expire at the 2029 annual meeting.
“The following two Class II directors were re-elected by the votes indicated: For Withheld Broker Non-Votes Faheem Hasnain 92,301,637 26,667,876 45,450,098 Russell Cox 88,975,980 29,993,533 45,450,098”
Gossamer Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“April 8, 2026, Gossamer Bio, Inc. (the “Company”) received a written notice from the staff (the “Staff”) of the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), notifying the Company that, for the 30 consecutive business day period between February 24, 2026 through April 7, 2026, the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). Nasdaq’s w”
Gossamer Bio, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $41.9 million, or $0.19 per share, EPS $0.19 per share.
“On May 7, 2024, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2024.”
Gossamer Bio, Inc. entered into Chiesi Collaboration Agreement with Chiesi Farmaceutici S.p.A and Chiesi USA, Inc. (collectively, Chiesi) valued at Upfront payment of $160 million, plus up to $146 million in regulatory milestones and $180 million i (effective 2024-05-03).
“On May 3, 2024, Gossamer Bio, Inc. (“Gossamer” or the “Company”), GB002, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“GB002”), and Gossamer Bio 002 Ltd., a corporation organized and existing under the laws of Ireland and indirect wholly-owned subsidiary of the Company, entered into a global collaboration and license agreement (the “Chiesi Collaboration Agreement”) with Chiesi Farmaceutici S.p.A and Chiesi USA, Inc. (collectively, “Chiesi”). The collaboration is focused on the development and commercialization of seralutinib and licensed products including seralutinib and related licensed compounds (“Licensed Products”) in the US (“US Territory”) and the rest of the world (“ROW Territory”), for therapeutic, prophylactic and diagnostic uses in humans and animals, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) and other indications, as may be permitted under the Chiesi Co”
Steven Nathan was appointed as Class I director at Gossamer Bio, Inc..
“Steven Nathan, M.D. to serve as a Class I director effective March 11, 2024”
Skye Drynan was appointed as Class III director at Gossamer Bio, Inc..
“appointed Skye Drynan to serve as a Class III director effective March 11, 2024”
Gossamer Bio, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“On March 5, 2024 , Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter and fiscal year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.